Mats Rudling

List of Publications by Year
in descending order

75 papers	5,570 citations	71004 43 h-index	90395 73 g-index
77 all docs	77 docs citations	77 times ranked	7152 citing authors

#	Article	IF	Citations
1	Of mice and men: murine bile acids explain species differences in the regulation of bile acid and cholesterol metabolism. Journal of Lipid Research, 2020, 61, 480-491.	2.0	65
2	A Physiology-Based Model of Bile Acid Distribution and Metabolism Under Healthy and Pathologic Conditions in Human Beings. Cellular and Molecular Gastroenterology and Hepatology, 2020, 10, 149-170.	2.3	30
3	Regulation of bile acid metabolism in biliary atresia: reduction of FGF19 by Kasai portoenterostomy and possible relation to early outcome. Journal of Internal Medicine, 2020, 287, 534-545.	2.7	12
4	Overeating Saturated Fat Promotes Fatty Liver and Ceramides Compared With Polyunsaturated Fat: A Randomized Trial. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 6207-6219.	1.8	124
5	Energy restriction in obese women suggest linear reduction of hepatic fat content and time-dependent metabolic improvements. Nutrition and Diabetes, 2019, 9, 34.	1.5	12
6	Gallbladder bile supersaturated with cholesterol in gallstone patients preferentially develops from shortage of bile acids. Journal of Lipid Research, 2019, 60, 498-505.	2.0	21
7	Asynchronous rhythms of circulating conjugated and unconjugated bile acids in the modulation of human metabolism. Journal of Internal Medicine, 2018, 284, 546-559.	2.7	26
8	An FXR Agonist Reduces Bile Acid Synthesis Independently of Increases in FGF19 in Healthy Volunteers. Gastroenterology, 2018, 155, 1012-1016.	0.6	44
9	Treatment with the natural <scp>FXR</scp> agonist chenodeoxycholic acid reduces clearance of plasma <scp>LDL</scp> whilst decreasing circulating <scp>PCSK</scp>9, lipoprotein(a) and apolipoprotein Câ€‹<scp>III</scp>. Journal of Internal Medicine, 2017, 281, 575-585.	2.7	52
10	Acute caloric restriction counteracts hepatic bile acid and cholesterol deficiency in morbid obesity. Journal of Internal Medicine, 2017, 281, 507-517.	2.7	26
11	Cholestyramine treatment of healthy humans rapidly induces transient hypertriglyceridemia when treatment is initiated. American Journal of Physiology - Endocrinology and Metabolism, 2017, 313, E167-E174.	1.8	24
12	Mice Abundant in Muricholic Bile Acids Show Resistance to Dietary Induced Steatosis, Weight Gain, and to Impaired Glucose Metabolism. PLoS ONE, 2016, 11, e0147772.	1.1	43
13	Understanding mouse bile acid formation: Is it time to unwind why mice and rats make unique bile acids?. Journal of Lipid Research, 2016, 57, 2097-2098.	2.0	19
14	Impaired Cholesterol Efflux Capacity of High-Density Lipoprotein Isolated From Interstitial Fluid in Type 2 Diabetes Mellitusâ€"Brief Report. Arteriosclerosis, Thrombosis, and Vascular Biology, 2016, 36, 787-791.	1.1	33
15	Circulating Hepcidin-25 Is Reduced by Endogenous Estrogen in Humans. PLoS ONE, 2016, 11, e0148802.	1.1	56
16	Influence of dietary sugar on cholesterol and bile acid metabolism inÂthe rat: Marked reduction of hepatic Abcg5/8 expression following sucrose ingestion. Biochemical and Biophysical Research Communications, 2015, 461, 592-597.	1.0	6
17	Authorsâ€™ response: Bile acids are important in the pathophysiology of IBS. Gut, 2015, 64, 851.2-852.	6.1	1
18	Letter to the Editor: Potential Role for FGF21 as a Mediator of Thyroid Hormone Effects on Metabolic Regulation. Journal of Clinical Endocrinology and Metabolism, 2015, 100, L130-L131.	1.8	1

#	Article	IF	Citations
19	Stimulation of Apical Sodium-Dependent Bile Acid Transporter Expands the Bile Acid Pool and Generates Bile Acids with Positive Feedback Properties. Digestive Diseases, 2015, 33, 376-381.	0.8	5
20	Potential role of milk fat globule membrane in modulating plasma lipoproteins, gene expression, and cholesterol metabolism in humans: a randomized study. American Journal of Clinical Nutrition, 2015, 102, 20-30.	2.2	110
21	Influence of physiological changes in endogenous estrogen on circulating PCSK9 and LDL cholesterol. Journal of Lipid Research, 2015, 56, 463-469.	2.0	70
22	Levels of atherogenic lipoproteins are unexpectedly reduced in interstitial fluid from type 2 diabetes patients. Journal of Lipid Research, 2015, 56, 1633-1639.	2.0	4
23	Specific inhibition of bile acid transport alters plasma lipids and GLP-1. BMC Cardiovascular Disorders, 2015, 15, 75.	0.7	49
24	Increased colonic bile acid exposure: a relevant factor for symptoms and treatment in IBS. Gut, 2015, 64, 84-92.	6.1	167
25	Muricholic bile acids are potent regulators of bile acid synthesis via a positive feedback mechanism. Journal of Internal Medicine, 2014, 275, 27-38.	2.7	83
26	The Arachidonic Acid Metabolome Serves as a Conserved Regulator of Cholesterol Metabolism. Cell Metabolism, 2014, 20, 787-798.	7.2	92
27	Role of Dietary Fats in Modulating Cardiometabolic Risk During Moderate Weight Gain: A Randomized Doubleâ€Blind Overfeeding Trial (LIPOGAIN Study). Journal of the American Heart Association, 2014, 3, e001095.	1.6	40
28	Thyroid hormone reduces PCSK9 and stimulates bile acid synthesis in humans. Journal of Lipid Research, 2014, 55, 2408-2415.	2.0	71
29	Influence of growth hormone on circulating fibroblast growth factor 21 levels in humans. Journal of Internal Medicine, 2013, 274, 227-232.	2.7	19
30	Endogenous Estrogens Lower Plasma PCSK9 and LDL Cholesterol But Not Lp(a) or Bile Acid Synthesis in Women. Arteriosclerosis, Thrombosis, and Vascular Biology, 2012, 32, 810-814.	1.1	82
31	Circulating Fibroblast Growth Factors as Metabolic Regulatorsâ€"A Critical Appraisal. Cell Metabolism, 2012, 16, 693-705.	7.2	184
32	Stimulation of murine biliary cholesterol secretion by thyroid hormone is dependent on a functional ABCG5/G8 complex. Hepatology, 2012, 56, 1828-1837.	3.6	42
33	Inhibition of Intestinal Bile Acid Transporter Slc10a2 Improves Triglyceride Metabolism and Normalizes Elevated Plasma Glucose Levels in Mice. PLoS ONE, 2012, 7, e37787.	1.1	32
34	Randomised clinical trial: the ileal bile acid transporter inhibitor A3309 vs. placebo in patients with chronic idiopathic constipation - a double-blind study. Alimentary Pharmacology and Therapeutics, 2011, 34, 41-50.	1.9	100
35	Pronounced variation in bile acid synthesis in humans is related to gender, hypertriglyceridaemia and circulating levels of fibroblast growth factor 19. Journal of Internal Medicine, 2011, 270, 580-588.	2.7	92
36	Lipid lowering with thyroid hormone and thyromimetics. Current Opinion in Lipidology, 2010, 21, 499-506.	1.2	63

#	Article	IF	Citations
37	Importance of Proprotein Convertase Subtilisin/Kexin Type 9 in the Hormonal and Dietary Regulation of Rat Liver Low-Density Lipoprotein Receptors. Endocrinology, 2009, 150, 1140-1146.	1.4	67
38	Dramatically Increased Intestinal Absorption of Cholesterol Following Hypophysectomy Is Normalized by Thyroid Hormone. Gastroenterology, 2008, 134, 1127-1136.	0.6	61
39	The thyroid hormone mimetic compound KB2115 lowers plasma LDL cholesterol and stimulates bile acid synthesis without cardiac effects in humans. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 663-667.	3.3	169
40	The Circulating Metabolic Regulator FGF21 Is Induced by Prolonged Fasting and PPARÎ± Activation in Man. Cell Metabolism, 2008, 8, 169-174.	7.2	441
41	PPARÎ± is a key regulator of hepatic FGF21. Biochemical and Biophysical Research Communications, 2007, 360, 437-440.	1.0	337
42	Lipoprotein profiles in plasma and interstitial fluid analyzed with an automated gel-filtration system. European Journal of Clinical Investigation, 2006, 36, 98-104.	1.7	111
43	Circulating intestinal fibroblast growth factor 19 has a pronounced diurnal variation and modulates hepatic bile acid synthesis in man. Journal of Internal Medicine, 2006, 260, 530-536.	2.7	355
44	Selective thyroid receptor modulation by GC-1 reduces serum lipids and stimulates steps of reverse cholesterol transport in euthyroid mice. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 10297-10302.	3.3	177
45	Bile Acid Synthesis in Humans Has a Rapid Diurnal Variation That Is Asynchronous With Cholesterol Synthesis. Gastroenterology, 2005, 129, 1445-1453.	0.6	181
46	Growth Hormone Induces Low-Density Lipoprotein Clearance but not Bile Acid Synthesis in Humans. Arteriosclerosis, Thrombosis, and Vascular Biology, 2004, 24, 349-356.	1.1	40
47	Bile acid synthesis is increased in chilean hispanics with gallstones and in gallstone high-risk Mapuche Indians. Gastroenterology, 2004, 126, 741-748.	0.6	55
48	Monitoring hepatic cholesterol 7Î±-hydroxylase activity by assay of the stable bile acid intermediate 7Î±-hydroxy-4-cholesten-3-one in peripheral blood. Journal of Lipid Research, 2003, 44, 859-866.	2.0	172
49	Pharmacological interference with intestinal bile acid transport reduces plasma cholesterol in LDL receptor/apoE deficiency. FASEB Journal, 2003, 17, 265-267.	0.2	21
50	Leptin Induces the Hepatic High Density Lipoprotein Receptor Scavenger Receptor B Type I (SR-BI) but Not Cholesterol 7Î±-Hydroxylase (Cyp7a1) in Leptin-deficient (ob/ob) Mice. Journal of Biological Chemistry, 2003, 278, 43224-43228.	1.6	71
51	Prolonged Stimulation of the Adrenals by Corticotropin Suppresses Hepatic Low-Density Lipoprotein and High-Density Lipoprotein Receptors and Increases Plasma Cholesterol. Endocrinology, 2002, 143, 1809-1816.	1.4	17
52	Regulation of Hepatic Low-Density Lipoprotein Receptor, 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase, and Cholesterol 7Î±-Hydroxylase mRNAs in Human Liver. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 4307-4313.	1.8	51
53	Requirement for Thyroid Hormone Receptor Î² in T3Regulation of Cholesterol Metabolism in Mice. Molecular Endocrinology, 2002, 16, 1767-1777.	3.7	122
54	Growth hormone reduces plasma cholesterol in LDL receptorâ€deficient mice. FASEB Journal, 2001, 15, 1350-1356.	0.2	28

#	Article	IF	Citations
55	Endotoxin suppresses mouse hepatic low-density lipoprotein-receptor expression via a pathway independent of the toll-like receptor 4. Hepatology, 1999, 30, 1252-1256.	3.6	14
56	Effects of growth hormone on hepatic cholesterol metabolism. Lessons from studies in rats and humans. Growth Hormone and IGF Research, 1999, 9, 1-7.	0.5	15
57	Bile acids and lipoprotein metabolism. Current Opinion in Lipidology, 1999, 10, 269-274.	1.2	23
58	Bile acid synthesis in primary cultures of rat and human hepatocytes. Hepatology, 1998, 27, 615-620.	3.6	46
59	Hepatic cholesterol metabolism in experimental nephrotic syndrome. Lipids, 1998, 33, 165-169.	0.7	9
60	Lipoprotein Metabolism in the Fat Zucker Rat: Reduced Basal Expression but Normal Regulation of Hepatic Low Density Lipoprotein Receptors*. Endocrinology, 1997, 138, 3276-3282.	1.4	26
61	Hepatic cholesterol metabolism in human obesity. Hepatology, 1997, 25, 1447-1450.	3.6	88
62	Growth hormone and bile acid synthesis. Key role for the activity of hepatic microsomal cholesterol 7alpha-hydroxylase in the rat.. Journal of Clinical Investigation, 1997, 99, 2239-2245.	3.9	64
63	Endotoxin suppresses rat hepatic low-density lipoprotein receptor expression. Biochemical Journal, 1996, 313, 873-878.	1.7	23
64	Regulation of rat hepatic low density lipoprotein receptors. In vivo stimulation by growth hormone is not mediated by insulin-like growth factor I.. Journal of Clinical Investigation, 1996, 97, 292-299.	3.9	59
65	Influence of bezafibrate on hepatic cholesterol metabolism in gallstone patients: Reduced activity of cholesterol 7Î±-hydroxylase. Hepatology, 1995, 21, 1025-1030.	3.6	62
66	Loss of resistance to dietary cholesterol in the rat after hypophysectomy: importance of the presence of growth hormone for hepatic low density lipoprotein-receptor expression.. Proceedings of the National Academy of Sciences of the United States of America, 1993, 90, 8851-8855.	3.3	51
67	Stimulation of rat hepatic low density lipoprotein receptors by glucagon. Evidence of a novel regulatory mechanism in vivo.. Journal of Clinical Investigation, 1993, 91, 2796-2805.	3.9	62
68	Importance of growth hormone for the induction of hepatic low density lipoprotein receptors.. Proceedings of the National Academy of Sciences of the United States of America, 1992, 89, 6983-6987.	3.3	233
69	Hepatic mRNA levels for the LDL receptor and HMG-CoA reductase show coordinate regulation in vivo.. Journal of Lipid Research, 1992, 33, 493-501.	2.0	112
70	Hepatic mRNA levels for the LDL receptor and HMG-CoA reductase show coordinate regulation in vivo. Journal of Lipid Research, 1992, 33, 493-501.	2.0	97
71	Bile acid sequestrants: Mechanisms of action on bile acid and cholesterol metabolism. European Journal of Clinical Pharmacology, 1991, 40, S53-S58.	0.8	36
72	Regulation of hepatic cholesterol metabolism in humans: stimulatory effects of cholestyramine on HMG-CoA reductase activity and low density lipoprotein receptor expression in gallstone patients.. Journal of Lipid Research, 1990, 31, 2219-2226.	2.0	87

#	Article	IF	Citations
73	Regulation of hepatic cholesterol metabolism in humans: stimulatory effects of cholestyramine on HMG-CoA reductase activity and low density lipoprotein receptor expression in gallstone patients. Journal of Lipid Research, 1990, 31, 2219-26.	2.0	66
74	Novel Effects of Histamine on Lipoprotein Metabolism: Suppression of Hepatic Low Density Lipoprotein Receptor Expression and Reduction of Plasma High Density Lipoprotein Cholesterol in the Rat. , 0, .		4
75	Lipoprotein Metabolism in the Fat Zucker Rat: Reduced Basal Expression but Normal Regulation of Hepatic Low Density Lipoprotein Receptors. , 0, .		6